Clinical Study to Assess the Performance of the Dialyzer With Endexo™

Inclusion Criteria

• •1. Must be an adult, older than 22 years of age.
• •2. Has been prescribed in-center thrice-weekly HD continuously for at least 180 days prior to the date of signed informed consent
• •3. Has been prescribed the Optiflux F160NR dialyzer continuously for at least 30 days prior to the date of signed informed consent
• •4. Has a prescribed HD treatment time ≥180 minutes (3 hours) and ≤270 minutes (4.5 hours)
• •5. Has been on heparin anticoagulation for dialysis and has had no change in heparin prescription within 14 days prior to the date of signed informed consent
• •6. Has a most recent single pool Kt/V (spKt/V) ≥1.2 within 45 days prior to the date of a signed informed consent
• •7. Has a most recent hemoglobin ≥9 g/dL within 45 days prior to the date of a signed informed consent
• •8. Has a most recent platelet count ≥100,000/mm3 within 45 days prior to the date of a signed informed consent
• •9. A female of childbearing potential must have a negative serum pregnancy test at the time of screening and agree to use an acceptable method of contraception during the study